Kate Ryan Kuhlman1, Michael R Irwin, Patricia A Ganz, Catherine M Crespi, Laura Petersen, Arash Asher, Julienne E Bower. 1. From the Department of Psychology (Kuhlman, Bower), Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior (Kuhlman, Irwin, Bower), Jonsson Comprehensive Cancer Center (Ganz, Crespi, Petersen, Bower), Department of Biostatistics, Fielding School of Public Health (Crespi), and David Geffen School of Medicine (Irwin, Ganz), University of California Los Angeles; and Samuel Oschin Comprehensive Cancer Institute (Asher), Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
OBJECTIVE: The aim of the study was to investigate hypothalamic-pituitary-adrenal axis (HPA axis) functioning as a neurobiological risk factor for depressive symptoms in an ongoing longitudinal, observational study of women undergoing treatment and recovery from breast cancer. Many women with breast cancer experience depressive symptoms that interfere with their treatment, recovery, and quality of life. Psychosocial risk factors for depression among patients with cancer and survivors have been identified, yet neurobiological risk factors in this population remain largely unexamined. METHODS: Women recently diagnosed with early-stage breast cancer (N = 135) were enrolled before starting neoadjuvant/adjuvant treatment (radiation, chemotherapy, endocrine therapy). At baseline, participants collected saliva samples to measure diurnal HPA axis functioning for 3 days: at waking, 30 minutes after waking, 8 hours after waking, and bedtime. Participants also completed a standardized measure of depressive symptoms (Center for Epidemiological Studies-Depression Scale) at baseline and 6 months after completion of primary treatment. Multivariate regression was used to predict continuous depressive symptoms at 6-month posttreatment from continuous depressive symptoms at baseline, cortisol awakening response (CAR), and other measures of diurnal HPA axis functioning. RESULTS: The magnitude of CAR predicted changes in depressive symptoms over time, such that women with a higher CAR showed a greater increase from baseline to 6-month posttreatment (b = 5.67, p = .023). Diurnal slope and total cortisol output were not associated with concurrent depressive symptoms or their change over time. CONCLUSIONS: Elevated CAR may be a neurobiological risk factor for increases in depressive symptoms in the months after breast cancer treatment and warrants further investigation.
OBJECTIVE: The aim of the study was to investigate hypothalamic-pituitary-adrenal axis (HPA axis) functioning as a neurobiological risk factor for depressive symptoms in an ongoing longitudinal, observational study of women undergoing treatment and recovery from breast cancer. Many women with breast cancer experience depressive symptoms that interfere with their treatment, recovery, and quality of life. Psychosocial risk factors for depression among patients with cancer and survivors have been identified, yet neurobiological risk factors in this population remain largely unexamined. METHODS:Women recently diagnosed with early-stage breast cancer (N = 135) were enrolled before starting neoadjuvant/adjuvant treatment (radiation, chemotherapy, endocrine therapy). At baseline, participants collected saliva samples to measure diurnal HPA axis functioning for 3 days: at waking, 30 minutes after waking, 8 hours after waking, and bedtime. Participants also completed a standardized measure of depressive symptoms (Center for Epidemiological Studies-Depression Scale) at baseline and 6 months after completion of primary treatment. Multivariate regression was used to predict continuous depressive symptoms at 6-month posttreatment from continuous depressive symptoms at baseline, cortisol awakening response (CAR), and other measures of diurnal HPA axis functioning. RESULTS: The magnitude of CAR predicted changes in depressive symptoms over time, such that women with a higher CAR showed a greater increase from baseline to 6-month posttreatment (b = 5.67, p = .023). Diurnal slope and total cortisol output were not associated with concurrent depressive symptoms or their change over time. CONCLUSIONS: Elevated CAR may be a neurobiological risk factor for increases in depressive symptoms in the months after breast cancer treatment and warrants further investigation.
Authors: T O Harris; S Borsanyi; S Messari; K Stanford; S E Cleary; H M Shiers; G W Brown; J Herbert Journal: Br J Psychiatry Date: 2000-12 Impact factor: 9.319
Authors: Kate Ryan Kuhlman; Guido G Urizar; Theodore F Robles; Ilona S Yim; Christine Dunkel Schetter Journal: Psychoneuroendocrinology Date: 2019-05-20 Impact factor: 4.905
Authors: Maira Karan; Danny Rahal; David M Almeida; Julienne E Bower; Michael R Irwin; Heather McCreath; Teresa Seeman; Andrew J Fuligni Journal: Psychoneuroendocrinology Date: 2021-07-31 Impact factor: 4.693
Authors: Amy Jo Lisanti; Abigail Demianczyk; Maria G Vogiatzi; Ryan Quinn; Jesse Chittams; Rebecca Hoffman; Barbara Medoff-Cooper Journal: Biol Res Nurs Date: 2022-03-19 Impact factor: 2.318
Authors: Kate Ryan Kuhlman; Jessica J Chiang; Julienne E Bower; Michael R Irwin; Teresa E Seeman; Heather E McCreath; David M Almeida; Ronald E Dahl; Andrew J Fuligni Journal: Dev Psychopathol Date: 2020-08
Authors: Andrew W Manigault; Kate R Kuhlman; Michael R Irwin; Steve W Cole; Patricia A Ganz; Catherine M Crespi; Julienne E Bower Journal: Brain Behav Immun Date: 2021-03-09 Impact factor: 7.217